RoosterBio
Supplies high-volume, well-characterized adult human mesenchymal stem cells (hMSCs) and engineered media systems for bioprinting and regenerative medicine, reducing cell costs from >$1,000 to <$10 per million cells.
- CEO / Founder
- Tim Kelly
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $28.2M
- Latest Round
- Series C
- Key Investors
- Dynamk Capital; Maryland Stem Cell Research Fund (MSCRF)
Technology & Products
Key Products
RoosterRTP™-hBM-50M-XF (Ready-to-Print stem cells); hMSC bioprocessing systems; Bioprocess media systems; Genetic engineering tools; Extracellular vesicle (EV) production solutions; cGMP-compatible products like RoosterGEM™
Technological Advantage
Proprietary scalable biomanufacturing platforms for hMSCs and EVs, with chemically defined, xeno-free media systems that achieve high cell viability and consistency, supported by process development expertise and regulatory experience.
Differentiation
Value Proposition
Accelerates bioprinting and cell therapy development by providing standardized, scalable hMSC systems that cut weeks from the cellular bioprinting process, enabling faster clinical translation and reducing costs by over 99% per million cells.
How They Differentiate
Offers the first commercial Ready-to-Print stem cell products specifically for bioprinting, with standardized, scalable hMSC systems that reduce costs by over 99% per million cells compared to traditional sources, unlike competitors focused on general cell culture media or bioprinting hardware.
Market & Competition
Target Customers
Advanced therapy product developers and manufacturers in pharma and biotech, academic and government researchers in regenerative medicine, tissue engineering, and 3D bioprinting.
Industry Verticals
Regenerative Medicine; Cell Therapy; Tissue Engineering; Bioprinting; Biotechnology
Competitors
STEMCELL Technologies; CellGenix; Precise Bio; Aspect Biosystems
Growth & Milestones
Growth Metrics
Revenue ~$8.9M annually; serves 200–500+ global customers; team size ~60 employees.
Major Milestones
Founded in 2013; Launched first Ready-to-Print stem cell product in 2015; Raised $15M Series B in 2019 led by Dynamk Capital; Launched RoosterGEM™ cGMP-compatible product in 2021; Raised $12M Series C in 2024
Notable Customers
AGC Biologics; Sartorius; Nikon CeLL Innovation; BioSolution Designs; Tissue Regeneration Therapeutics; Gencure; ExoPharm; CELLINK; PBS Biotech